Literature DB >> 25862484

Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: a case series.

Johann Otto Pelz1, Christopher Fricke, Dorothee Saur, Joseph Classen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25862484     DOI： 10.1007/s00415-015-7734-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases.

Authors:  Ichiro Miyai; Mizuki Ito; Noriaki Hattori; Masahito Mihara; Megumi Hatakenaka; Hajime Yagura; Gen Sobue; Masatoyo Nishizawa
Journal:  Neurorehabil Neural Repair       Date:  2011-12-02       Impact factor: 3.919

Review 2.  Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors.

Authors:  Asbjørn Hróbjartsson; Ann Sofia Skou Thomsen; Frida Emanuelsson; Britta Tendal; Jørgen Hilden; Isabelle Boutron; Philippe Ravaud; Stig Brorson
Journal:  CMAJ       Date:  2013-01-28       Impact factor: 8.262

3.  In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig.

Authors:  N Vibert; P P Vidal
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

4.  Scale for the assessment and rating of ataxia: development of a new clinical scale.

Authors:  T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

5.  Effects of acetyl-DL-leucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy.

Authors:  C Ferber-Viart; C Dubreuil; P P Vidal
Journal:  Audiol Neurootol       Date:  2008-07-29       Impact factor: 1.854

6.  Intensive coordinative training improves motor performance in degenerative cerebellar disease.

Authors:  W Ilg; M Synofzik; D Brötz; S Burkard; M A Giese; L Schöls
Journal:  Neurology       Date:  2009-10-28       Impact factor: 9.910

7.  Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients.

Authors:  Anja Weyer; Michael Abele; Tanja Schmitz-Hübsch; Beate Schoch; Markus Frings; Dagmar Timmann; Thomas Klockgether
Journal:  Mov Disord       Date:  2007-08-15       Impact factor: 10.338

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

9.  Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series.

Authors:  Michael Strupp; Julian Teufel; Maximilian Habs; Regina Feuerecker; Carolin Muth; Bart P van de Warrenburg; Thomas Klopstock; Katharina Feil
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849
  9 in total
  5 in total

1.  An anecdotal report by an Oxford basic neuroscientist: effects of acetyl-DL-leucine on cognitive function and mobility in the elderly.

Authors:  Frances Platt; Michael Strupp
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

Review 2.  Gait ataxia in humans: vestibular and cerebellar control of dynamic stability.

Authors:  Roman Schniepp; Ken Möhwald; Max Wuehr
Journal:  J Neurol       Date:  2017-04-10       Impact factor: 4.849

3.  Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.

Authors:  Katharina Feil; Christine Adrion; Julian Teufel; Sylvia Bösch; Jens Claassen; Ilaria Giordano; Holger Hengel; Heike Jacobi; Thomas Klockgether; Thomas Klopstock; Wolfgang Nachbauer; Ludger Schöls; Claudia Stendel; Ellen Uslar; Bart van de Warrenburg; Ingrid Berger; Ivonne Naumann; Otmar Bayer; Hans-Helge Müller; Ulrich Mansmann; Michael Strupp
Journal:  BMC Neurol       Date:  2017-01-10       Impact factor: 2.474

4.  Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series.

Authors:  Roman Schniepp; Michael Strupp; Max Wuehr; Klaus Jahn; Marianne Dieterich; Thomas Brandt; Katharina Feil
Journal:  Cerebellum Ataxias       Date:  2016-04-12

5.  Beneficial Effects of Acetyl-DL-Leucine (ADLL) in a Mouse Model of Sandhoff Disease.

Authors:  Ecem Kaya; David A Smith; Claire Smith; Barry Boland; Michael Strupp; Frances M Platt
Journal:  J Clin Med       Date:  2020-04-08       Impact factor: 4.964
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.